Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MultiCell Technologies has reported its completion of all upfront license fees related to its acquisition of MCT-125, a drug candidate being developed as a treatment for fatigue associated with multiple sclerosis.
Subscribe to our email newsletter
The payment was completed pursuant to the terms of the amended license agreement with Amarin Neuroscience. MultiCell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time it is under patent protection. Under the terms of the agreement, Amarin could receive up to $275 million in milestone payments and cumulative royalty payments.
MCT-125 targets fatigue associated with multiple sclerosis. About two million people worldwide are afflicted with multiple sclerosis, and approximately 70% of them report fatigue as the worst symptom of their disease.
In a phase II trial conducted in the UK by Amarin, MCT-125 (then known as LAX-202) demonstrated efficacy in significantly reducing the levels of fatigue, with few if any side effects, in all multiple sclerosis patient populations enrolled in the study including relapse-remitting, secondary progressive and primary progressive.